Anacor Pharma (ANAC) Misses Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Jefferies Cuts Price Target on Anacor Pharma (ANAC) to $105 Following a 4Q EPS Miss
March 1, 2016 9:12 AM ESTJefferies maintained a Buy rating on Anacor Pharmaceuticals (NASDAQ: ANAC), and cut the price target to $105.00 (from $159.00), following the company's 4Q earnings report. ANAC reported an EPS loss of $0.43, missing Jefferies' estimates for a loss of $0.31. Management attributed the miss to short term competitive... More
